1. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor
   Xiaotian Song et al, 2021, Frontiers in Immunology CrossRef
2. In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity
   Theodoros Eleftheriadis et al, 2020, Archivum Immunologiae et Therapiae Experimentalis CrossRef
3. Inhibition of acetyl‑CoA carboxylase by PP‑7a exerts beneficial effects on metabolic dysregulation in a mouse model of diet‑induced obesity
   Tianya Liu et al, 2020, Experimental and Therapeutic Medicine CrossRef
4. Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy
   Angèle Luby et al, 2021, Cancers CrossRef
5. Low Levels of Serum Tryptophan Underlie Skeletal Muscle Atrophy
   Soranobu Ninomiya et al, 2020, Nutrients CrossRef
6. IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
   Adaobi Amobi-McCloud et al, 2021, Frontiers in Immunology CrossRef
7. The effect of lipid metabolism disorder on patients with hyperuricemia using Multi-Omics analysis
   Lili Ma et al, 2023, Scientific Reports CrossRef
8. What May Constrain the Success of Indoleamine 2,3-Dioxygenase 1 Inhibitors in Cancer Immunotherapy?
   Theodoros Eleftheriadis, 2018, Frontiers in Immunology CrossRef
9. The Kynurenine Pathway—New Linkage between Innate and Adaptive Immunity in Autoimmune Endocrinopathies
   Anna Krupa et al, 2021, International Journal of Molecular Sciences CrossRef